Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Povetacicept in Adults With Immunoglobulin A Nephropathy (RAINIER)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 20 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Povetacicept (Primary)
Indications IgA nephropathy
Focus Registrational; Therapeutic Use
Acronyms RAINIER
Sponsors Alpine Immune Sciences

Most Recent Events

13 Jan 2026 According to a Zai Lab media release, interim analysis of this global phase 3 RAINIER study in IgAN is expected in 1H 2026.
08 Nov 2025 According to a Vertex Pharma media release, the RAINIER study design was presented as a poster (FR-PO0813) during ASN Kidney Week.
06 Nov 2025 According to a Zai Lab media release, Vertex has completed full enrollment of the Phase 3 study, including the interim analysis cohort for potential accelerated approval in the U.S.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com